false
Anshul Mangal
Groundbreaking biotech entrepreneur, executive, and investor, dedicated to delivering transformative treatments to the patients who need them. Pioneered the industrialization of advanced therapeutics, including some of the earliest commercially approved cell and gene therapies, radioligand treatments, RNA-based therapies, and cutting-edge biologics. Created the leading global biologics and advanced therapy engineering consulting firm and developed the largest cell and gene therapy manufacturing footprint in the world. Deeply committed to advancing next-generation medicines, serves on multiple boards, philanthropic organizations, and patient-advocacy groups, including IQHQ, Alliance for Regenerative Medicines, and Alliance for mRNA Medicines.
-
Read: Challenges & Opportunities in Cell and Gene Therapy Challenges & Opportunities in Cell and Gene Therapy
-
Read: US Crackdown on Chinese Clinical Trials: What’s at Stake for Biopharma? Discover -
Read: Will BIOSECURE Boost US Pharma? Discover -
Read: The Bottom Line on Chevron's Overturn Discover -
Read: Perspectives on the Future of the BIOSECURE Act Discover -
Read: Bracing for Impact of BIOSECURE Act Discover -
Read: When Should Biopharma Companies Buy, Partner or Develop Innovative Assets? Discover -
Read: Strategic Portfolio Management in Cell and Gene Therapy: Keys to Growth and Impact Discover -
Read: Navigating Cell and Gene Therapy Acquisitions: A Strategic Blueprint Manufacturing - Cell Therapies - Gene Therapies
Navigating Cell and Gene Therapy Acquisitions: A Strategic Blueprint
|
Loading...
You've reach the end